Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
Objective of this study is to determine if, in the era of novel drugs, high dose therapy
(HDT) is still necessary in the initial management of multiple myeloma in younger patients.
HDT as compared to conventional dose treatment would be considered superior if it
significantly prolongs Progression-free survival (by at least 9 months).
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Toulouse
Collaborators:
Celgene Corporation Dana-Farber Cancer Institute Janssen-Cilag Ltd.